

R&D Pipelines

Status as of March 2026

SYNBIAS

GEMINI

#	Product	Class	CAS Number	Therapeutic Area	SAMPLES	STATUS
1	CLADRIBINE	Nucleoside	4291-63-8	Oncology	✓	
2	CLADRIBINE -PREMIX	Nucleoside	n.a.	Oncology		
3	DAUNORUBICIN HYDROCHLORIDE	Anthracycline	23541-50-6	Oncology	✓	
4	CAMSIRUBICIN	Anthracycline	236095-24-2	Oncology	✓	
5	ALDOXORUBICIN	Anthracycline	1361644-26-9	Oncology	✓	(CLINICAL TRIALS)
6	BERUBICIN	Anthracycline	293736-67-1	Oncology	✓	(CLINICAL TRIALS)
7	DAUNOMUSTINE	Anthracycline	n.a.	Oncology	✓	
8	FLUDARABINE	Nucleoside	75607-67-9	Oncology	✓	
9	EVEROLIMUS	mTOR Inhibitor	159351-69-6	Oncology	✓	